• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

端粒生物学障碍疾病的进展和临床结局。

Disease progression and clinical outcomes in telomere biology disorders.

机构信息

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.

出版信息

Blood. 2022 Mar 24;139(12):1807-1819. doi: 10.1182/blood.2021013523.

DOI:10.1182/blood.2021013523
PMID:34852175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8952184/
Abstract

Dyskeratosis congenita related telomere biology disorders (DC/TBDs) are characterized by very short telomeres caused by germline pathogenic variants in telomere biology genes. Clinical presentations can affect all organs, and inheritance patterns include autosomal dominant (AD), autosomal recessive (AR), X-linked (XLR), or de novo. This study examined the associations between mode of inheritance with phenotypes and long-term clinical outcomes. Two hundred thirty-one individuals with DC/TBDs (144 male, 86.6% known genotype, median age at diagnosis 19.4 years [range 0 to 71.6]), enrolled in the National Cancer Institute's Inherited Bone Marrow Failure Syndrome Study, underwent detailed clinical assessments and longitudinal follow-up (median follow-up 5.2 years [range 0 to 36.7]). Patients were grouped by inheritance pattern, considering AD-nonTINF2, AR/XLR, and TINF2 variants separately. Severe bone marrow failure (BMF), severe liver disease, and gastrointestinal telangiectasias were more prevalent in AR/XLR or TINF2 disease, whereas pulmonary fibrosis developed predominantly in adults with AD disease. After adjusting for age at DC/TBD diagnosis, we observed the highest cancer risk in AR/XLR individuals. At last follow-up, 42% of patients were deceased with a median overall survival (OS) of 52.8 years (95% confidence interval [CI] 45.5-57.6), and the hematopoietic cell or solid organ transplant-free median survival was 45.3 years (95% CI 37.4-52.1). Significantly better OS was present in AD vs AR/XLR/TINF2 disease (P < .01), while patients with AR/XLR and TINF2 disease had similar survival probabilities. This long-term study of the clinical manifestations of DC/TBDs creates a foundation for incorporating the mode of inheritance into evidence-based clinical care guidelines and risk stratification in patients with DC/TBDs. This trial was registered at www.clinicaltrials.gov as #NCT00027274.

摘要

先天性角化不良相关端粒生物学疾病(DC/TBDs)的特征是端粒非常短,这是由端粒生物学基因的种系致病性变异引起的。临床表现可影响所有器官,遗传模式包括常染色体显性(AD)、常染色体隐性(AR)、X 连锁(XLR)或新生。本研究探讨了遗传方式与表型和长期临床结局之间的关系。231 名患有 DC/TBDs 的个体(144 名男性,86.6%已知基因型,诊断时的中位年龄为 19.4 岁[范围 0 至 71.6 岁]),参加了国家癌症研究所的遗传性骨髓衰竭综合征研究,接受了详细的临床评估和纵向随访(中位随访时间为 5.2 年[范围 0 至 36.7 年])。根据遗传模式将患者分组,分别考虑 AD-非 TINF2、AR/XLR 和 TINF2 变异。严重骨髓衰竭(BMF)、严重肝病和胃肠道毛细血管扩张症在 AR/XLR 或 TINF2 疾病中更为常见,而肺纤维化主要发生在 AD 疾病的成年人中。在调整 DC/TBD 诊断时的年龄后,我们观察到 AR/XLR 个体的癌症风险最高。在最后一次随访时,42%的患者死亡,中位总生存期(OS)为 52.8 年(95%置信区间[CI]45.5-57.6),造血细胞或实体器官移植无失败的中位生存时间为 45.3 年(95%CI 37.4-52.1)。AD 与 AR/XLR/TINF2 疾病相比,OS 显著更好(P<.01),而 AR/XLR 和 TINF2 疾病患者的生存概率相似。本研究对 DC/TBD 临床表现进行了长期研究,为将遗传方式纳入 DC/TBD 患者基于证据的临床护理指南和风险分层奠定了基础。该试验在 www.clinicaltrials.gov 注册,编号为 NCT00027274。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0701/8952184/abb254e2ef53/bloodBLD2021013523absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0701/8952184/abb254e2ef53/bloodBLD2021013523absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0701/8952184/abb254e2ef53/bloodBLD2021013523absf1.jpg

相似文献

1
Disease progression and clinical outcomes in telomere biology disorders.端粒生物学障碍疾病的进展和临床结局。
Blood. 2022 Mar 24;139(12):1807-1819. doi: 10.1182/blood.2021013523.
2
Genotype and Associated Cancer Risk in Individuals With Telomere Biology Disorders.端粒生物学紊乱个体的基因型与相关癌症风险
JAMA Netw Open. 2024 Dec 2;7(12):e2450111. doi: 10.1001/jamanetworkopen.2024.50111.
3
Dyskeratosis Congenita and Related Telomere Biology Disorders先天性角化不良及相关端粒生物学障碍
4
Progression of liver disease and portal hypertension in dyskeratosis congenita and related telomere biology disorders.先天性角化不良症及相关端粒生物学疾病中的肝脏疾病和门静脉高压进展。
Hepatology. 2023 Dec 1;78(6):1777-1787. doi: 10.1097/HEP.0000000000000461. Epub 2023 May 16.
5
An update on the biology and management of dyskeratosis congenita and related telomere biology disorders.先天性角化不良症及相关端粒生物学疾病的生物学和治疗进展。
Expert Rev Hematol. 2019 Dec;12(12):1037-1052. doi: 10.1080/17474086.2019.1662720. Epub 2019 Sep 10.
6
Dyskeratosis congenita and telomere biology disorders.先天性角化不良和端粒生物学障碍。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):637-648. doi: 10.1182/hematology.2022000394.
7
Editing TINF2 as a potential therapeutic approach to restore telomere length in dyskeratosis congenita.编辑 TINF2 作为一种潜在的治疗方法,以恢复先天性角化不良症中的端粒长度。
Blood. 2022 Aug 11;140(6):608-618. doi: 10.1182/blood.2021013750.
8
Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder.先天性角化不良(一种端粒生物学障碍)中肺功能测试的预后意义
ERJ Open Res. 2019 Nov 15;5(4). doi: 10.1183/23120541.00209-2019. eCollection 2019 Oct.
9
Telomere biology disorders may manifest as common variable immunodeficiency (CVID).端粒生物学障碍可能表现为普通变异型免疫缺陷(CVID)。
Clin Immunol. 2023 Dec;257:109837. doi: 10.1016/j.clim.2023.109837. Epub 2023 Nov 8.
10
Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation.先天性角化不良/端粒生物学障碍患者因骨髓衰竭或骨髓增生异常综合征行异基因造血细胞移植:不使用放疗的非清髓性预处理、单中心、单臂、开放标签试验。
Transplant Cell Ther. 2024 Oct;30(10):1005.e1-1005.e17. doi: 10.1016/j.jtct.2024.07.007. Epub 2024 Jul 11.

引用本文的文献

1
PUMA-induced apoptosis drives bone marrow failure and genomic instability in telomerase-deficient mice.PUMA诱导的细胞凋亡导致端粒酶缺陷小鼠的骨髓衰竭和基因组不稳定。
Cell Death Differ. 2025 Aug 19. doi: 10.1038/s41418-025-01557-w.
2
The TP53 tumor suppressor gene: From molecular biology to clinical investigations.TP53肿瘤抑制基因:从分子生物学到临床研究
J Intern Med. 2025 Aug;298(2):78-96. doi: 10.1111/joim.20106. Epub 2025 Jun 16.
3
Polygenic modifiers impact penetrance and expressivity in telomere biology disorders.多基因修饰因子影响端粒生物学障碍中的外显率和表现度。

本文引用的文献

1
Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations.具有家族性血液学和/或肺部表现的成年人中端粒生物学紊乱的患病率和表型。
Blood Adv. 2020 Oct 13;4(19):4873-4886. doi: 10.1182/bloodadvances.2020001721.
2
Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders.胃肠道出血:端粒生物学紊乱的表现。
J Pediatr. 2021 Mar;230:55-61.e4. doi: 10.1016/j.jpeds.2020.09.038. Epub 2020 Sep 21.
3
Combined lung and liver transplantation for noncirrhotic portal hypertension with severe hepatopulmonary syndrome in a patient with dyskeratosis congenita.
J Clin Invest. 2025 Jun 3. doi: 10.1172/JCI191107.
4
TERT c.3150 G > C (p.K1050N): a founder Ashkenazi Jewish variant associated with telomere biology disorders.端粒酶逆转录酶基因c.3150 G > C(p.K1050N):一种与端粒生物学障碍相关的阿什肯纳兹犹太人群奠基者变异。
NPJ Genom Med. 2025 Jun 2;10(1):46. doi: 10.1038/s41525-025-00501-8.
5
Germline PARN Variants in Telomere Biology Disorders and Challenges in Variant Curation.端粒生物学障碍中的种系PARN变异及变异整理面临的挑战
Mol Genet Genomic Med. 2025 Jun;13(6):e70107. doi: 10.1002/mgg3.70107.
6
hTERT Increases TRF2 to Induce Telomere Compaction and Extend Cell Replicative Lifespan.hTERT通过增加TRF2来诱导端粒压缩并延长细胞复制寿命。
Aging Cell. 2025 Aug;24(8):e70105. doi: 10.1111/acel.70105. Epub 2025 May 15.
7
Shorter Telomeres and Faster Telomere Attrition in Individuals With Five Syndromic Forms of Intellectual Disability: A Systematic Review and Meta-Analysis.五种智力障碍综合征个体的端粒较短且端粒损耗更快:一项系统评价和荟萃分析
J Intellect Disabil Res. 2025 Aug;69(8):641-654. doi: 10.1111/jir.13244. Epub 2025 Apr 24.
8
Extensive and persistent tongue ulceration is an early character of dyskeratosis congenita.广泛且持续的舌部溃疡是先天性角化不良的早期特征。
Orphanet J Rare Dis. 2025 Apr 21;20(1):192. doi: 10.1186/s13023-025-03721-4.
9
Loss of Ten1 in mice induces telomere shortening and models human dyskeratosis congenita.小鼠中Ten1的缺失会导致端粒缩短,并模拟人类先天性角化不良。
Sci Adv. 2025 Apr 11;11(15):eadp8093. doi: 10.1126/sciadv.adp8093.
10
Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohort.成人迟发性端粒生物学障碍:一项回顾性登记队列研究的临床见解与治疗结果
Blood Adv. 2025 May 13;9(9):2183-2191. doi: 10.1182/bloodadvances.2024014632.
先天性角化不良患者合并非肝硬化门静脉高压症及严重肝肺综合征的肺肝联合移植术
Pediatr Transplant. 2021 Mar;25(2):e13802. doi: 10.1111/petr.13802. Epub 2020 Aug 10.
4
Biallelic mutations in WRAP53 result in dysfunctional telomeres, Cajal bodies and DNA repair, thereby causing Hoyeraal-Hreidarsson syndrome.WRAP53 的双等位基因突变导致端粒、Cajal 体和 DNA 修复功能障碍,从而导致 Hoyeraal-Hreidarsson 综合征。
Cell Death Dis. 2020 Apr 17;11(4):238. doi: 10.1038/s41419-020-2421-4.
5
Combined Lung and Liver Transplantation for Short Telomere Syndrome.联合肺肝移植治疗短端粒综合征
Liver Transpl. 2020 Jun;26(6):840-844. doi: 10.1002/lt.25734. Epub 2020 May 2.
6
CNS manifestations in patients with telomere biology disorders.端粒生物学障碍患者的中枢神经系统表现
Neurol Genet. 2019 Oct 29;5(6):370. doi: 10.1212/NXG.0000000000000370. eCollection 2019 Dec.
7
Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder.先天性角化不良(一种端粒生物学障碍)中肺功能测试的预后意义
ERJ Open Res. 2019 Nov 15;5(4). doi: 10.1183/23120541.00209-2019. eCollection 2019 Oct.
8
, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation.核 exosome 靶向组件在家族性肺纤维化中发生突变,并且是端粒酶 RNA 成熟所必需的。
Genes Dev. 2019 Oct 1;33(19-20):1381-1396. doi: 10.1101/gad.326785.119. Epub 2019 Sep 5.
9
An update on the biology and management of dyskeratosis congenita and related telomere biology disorders.先天性角化不良症及相关端粒生物学疾病的生物学和治疗进展。
Expert Rev Hematol. 2019 Dec;12(12):1037-1052. doi: 10.1080/17474086.2019.1662720. Epub 2019 Sep 10.
10
Telomerase Variants in Patients with Cirrhosis Awaiting Liver Transplantation.肝硬化患者等待肝移植时的端粒酶变体。
Hepatology. 2019 Jun;69(6):2652-2663. doi: 10.1002/hep.30557. Epub 2019 Apr 9.